Abstract
Cardiovascular disease is the principal complication and the leading cause of death for patients with diabetes (DM). The efficacy of antihyperglycemic treatments on cardiovascular disease risk remains uncertain. Cardiovascular risk factors are affected by antihyperglycemic medications, as are many intermediate markers of cardiovascular disease. Here we summarize the evidence assessing the cardiovascular effects of antihyperglycemic medications with regard to risk factors, intermediate markers of disease, and clinical outcomes.
Original language | English (US) |
---|---|
Pages (from-to) | 145-161 |
Number of pages | 17 |
Journal | Clinical pharmacology and therapeutics |
Volume | 98 |
Issue number | 2 |
DOIs | |
State | Published - Aug 1 2015 |
ASJC Scopus subject areas
- Pharmacology
- Pharmacology (medical)